Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. respiratory infection
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Respiratory Infection Articles & Analysis

87 news found

Creative Diagnostics Announces High-Affinity Anti-Adenovirus Monoclonal Antibodies for Research and Assay Development

Creative Diagnostics Announces High-Affinity Anti-Adenovirus Monoclonal Antibodies for Research and Assay Development

In humans, 88 human adenoviruses have been identified in seven populations (A through G) and more than 50 different adenovirus serotypes have been identified, causing a wide range of diseases from mild respiratory infections in young children to life-threatening multi-organ disease in people with compromised immune systems. ...

ByCreative Diagnostics


Newborn Snoring: causes, effects, and solutions for peaceful sleep

Newborn Snoring: causes, effects, and solutions for peaceful sleep

What is Newborn Snoring? Oftentimes, newborns breathe noisily when they sleep. It may be caused due to extra mucus or dryness in their tiny nasal passages. However, if you notice your newborn baby actually snoring on a regular basis, consult with a doctor. If your snoring is causing issues with your partner or his/her snoring is irritating you at night, it is important that you seek timely ...

ByTannerMedico A/S - Asonor


How Ventilation Affects the Spread of COVID-19 Indoors

How Ventilation Affects the Spread of COVID-19 Indoors

That’s because COVID-19 spreads through respiratory droplets made when an infected person coughs, sneezes, or talks. ...

ByZeptive


Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast

(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...

ByBeyond Air Inc


MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022

The most common (≥25%) nonhematologic treatment-emergent AEs of any grade were diarrhea (43%), respiratory tract infection (41%), asthenic conditions (38%), musculoskeletal pain (32%), constipation (30%), nausea (29%), dizziness (27%) and abdominal pain (26%). ...

ByMorphoSys AG


Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference

Beyond Air To Participate in Piper’s 34th Annual Healthcare Conference

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023

(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

Beyond Air Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

Beyond Air Schedules Second Fiscal Quarter 2023 Financial Results Conference Call and Webcast

(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...

ByBeyond Air Inc


NanoPin Technologies Founder`s Study Demonstrates Greater Accuracy in Detecting TB in Infants

NanoPin Technologies Founder`s Study Demonstrates Greater Accuracy in Detecting TB in Infants

Approximately 10 million people develop “active” TB each year, which can be spread to others as a respiratory infection. According to the World Health Organization, people with active TB can infect up to 5-15 other people through close contact over the course of a year. ...

ByNanoPin Technologies Inc.


Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics

Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics

Davies-Cutting will contribute his extensive respiratory product development and industry expertise to the development and commercialization of Nob Hill Therapeutics’ first-of-its-kind DryNeb dry powder nebulizer inhalation drug delivery platform. ...

ByNob Hill Therapeutics


Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022

Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022

Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. ...

ByMicrobion Corporation


Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting

– New Data Further Support Potential for Patisiran to be an Effective Treatment for Cardiomyopathy of ATTR Amyloidosis – – Data from Exploratory Endpoints, Including Cardiac Biomarkers and Imaging, Suggest Favorable Impact of Patisiran on Measures of Cardiac Stress, Injury, Structure, and Function at Month 12 – – Treatment with Patisiran Demonstrated Generally ...

ByAlnylam Pharmaceuticals, Inc.


Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022

Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting 2022

– Company to Webcast Investor Event on September 30th at 8:00 p.m. ET – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment ...

ByAlnylam Pharmaceuticals, Inc.


Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. ...

ByOndine Biomedical Inc


Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

There are over 250 million people who suffer from lower respiratory tract infections (LTRI) every year and it is the 5th leading cause of death globally. The COVID-19 pandemic has highlighted the urgency for effective respiratory therapies. Inhaled anti-infectives dramatically improve the targeting of therapies to the site of ...

ByNob Hill Therapeutics


HiberGene Diagnostics introduces brand new UK division at NEQAS event

HiberGene Diagnostics introduces brand new UK division at NEQAS event

These high-quality testing solutions cover infectious and transmissible disease areas – including respiratory, sexually transmitted infections, hospital acquired infections, and women’s health – and are designed to revolutionise turnaround times for results in almost any setting, bringing cost and time savings while improving ...

ByHiberGene Diagnostics


N8 Medical Announces First-in-Human Use of its CeraShield™ Endotracheal Tube

N8 Medical Announces First-in-Human Use of its CeraShield™ Endotracheal Tube

Fouling of endotracheal tubes is associated with an increased risk of respiratory complications, increased antibiotic usage, infection and longer stays in the ICU. ...

ByN8 Medical, LLC


OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

OpGen Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia (HPN) Panel in the Lancet Respiratory Medicine

In the U.S., the Unyvero LRT and LRT BAL panels for rapid detection of lower respiratory tract infections such as pneumonia are FDA-cleared for tracheal aspirate samples and bronchoalveolar lavage fluids, respectively. Unyvero HPN and LRT BAL are the only syndromic multiplex PCR panels for lower respiratory tract infections that ...

ByOpGen, Inc.


Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

Amgen And Lance Bass Partner To Encourage People To Do A `Double Take` To Recognize The Early Signs Of Psoriatic Arthritis

THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...

ByAmgen Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT